This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
This study will evaluate the relation between the detection rate of minimal residual disease(MRD) and recurrence in HER2-positive early breast cancer patients in Asian countries. Blood will be regularly collected to check the presence of ctDNA in HER2-positive breast cancer patients who have scheduled for neoadjuvant chemotherapy followed by surgery. Prognostic data is also collected on the same patients. MRD is a small number of cancer cells left in the body during or after treatment. These cells have the potential to cause recurrence in cancer patients. MRD detection can help identify patients at increased risk of disease recurrence and guide treatment decisions. However, limited data are available on when ctDNA analysis should be done in the course of treatment, and what is the appropriate analysis method. This study will contribute to determining whether MRD detection using ctDNA is useful to predict the recurrence of HER2-positive early breast cancer patients. If this can be proven, it is expected that detection of MRD can use as a biomarker to assist in the de-/escalation of treatment strategies, therefore allowing to avoid overtreatment in patients at low risk, and to add more intensive treatment in patients at high risk. Moreover, studying with Asian countries, the results will become the basic data for approval of liquid biopsy.
Study Type
OBSERVATIONAL
Enrollment
60
National Cancer Center Hospital, Japan
Chuo-ku, Tokyo, Japan
RECRUITINGInvasive disease-free survival (IDFS)
ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer
Time frame: The duration from the date of surgery until the date of first documented the IDFS events, whichever comes first, up to 3 years.
Overall survival (OS)
Death attributable to any cause
Time frame: The duration from the date of surgery until the date of death from any cause, up to 3 years.
Disease-free survival (DFS)
IDFS events, ipsilateral or contralateral DCIS, second primary non-breast invasive cancer
Time frame: The duration from the date of surgery until the date of first documented the DFS events, whichever comes first, up to 3 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.